• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C 反应蛋白诱导的肝素化样本活化部分凝血活酶时间延长可被升高的因子 VIII 减弱。

C-reactive protein-induced activated partial thromboplastin time prolongation in heparinized samples is attenuated by elevated factor VIII.

机构信息

Departments of Pathology & Immunology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.

Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.

出版信息

Int J Lab Hematol. 2021 Feb;43(1):139-142. doi: 10.1111/ijlh.13314. Epub 2020 Aug 19.

DOI:10.1111/ijlh.13314
PMID:32812381
Abstract

INTRODUCTION

Activated partial thromboplastin time (aPTT) and antifactor Xa (anti-Xa) activity are used to monitor unfractionated heparin therapy in children on extracorporeal membrane oxygenation (ECMO). Elevated C-reactive protein (CRP) can prolong aPTT and cause discrepancy between these two assays. We aimed to evaluate CRP effect on aPTT and anti-Xa assays in the presence of heparin and to determine whether elevated CRP affects laboratory monitoring in pediatric ECMO patients.

MATERIALS AND METHODS

Citrated normal specimens were spiked with CRP, heparin, and recombinant factor VIII (FVIII) and followed by measurement of aPTT and anti-Xa activity. Additionally, aPTT, anti-Xa activity, FVIII, fibrinogen, and CRP were measured in 18 ECMO specimens.

RESULTS

Elevated CRP prolonged aPTT in normal specimens with or without heparin, but did not affect anti-Xa assay. In contrast, ECMO specimens showed similar aPTT and anti-Xa values regardless of CRP level. Elevated CRP in specimens was accompanied by increased fibrinogen and FVIII activity. Additional in vitro experiments confirmed that FVIII spiked simultaneously with CRP attenuated CRP-induced aPTT prolongation in heparinized specimens.

CONCLUSION

In vitro CRP-induced aPTT prolongation is not observed in pediatric ECMO samples due to concomitant FVIII increase. Discordant changes of CRP and FVIII in plasma could contribute to aPTT/anti-Xa discrepancies observed during heparin therapy in the pediatric population. The anti-Xa assay is preferable for heparin monitoring in pediatric ECMO settings.

摘要

简介

激活部分凝血活酶时间(aPTT)和抗因子 Xa(anti-Xa)活性用于监测体外膜肺氧合(ECMO)儿童的未分级肝素治疗。C 反应蛋白(CRP)升高可延长 aPTT,并导致这两种检测结果之间出现差异。我们旨在评估 CRP 对肝素存在下 aPTT 和抗-Xa 检测的影响,并确定 CRP 升高是否会影响儿科 ECMO 患者的实验室监测。

材料和方法

用 CRP、肝素和重组因子 VIII(FVIII)对枸橼酸盐正常标本进行加标,并随后测量 aPTT 和抗-Xa 活性。此外,在 18 个 ECMO 标本中测量了 aPTT、抗-Xa 活性、FVIII、纤维蛋白原和 CRP。

结果

CRP 升高可延长正常标本中的 aPTT,无论是否存在肝素,但不影响抗-Xa 检测。相比之下,ECMO 标本无论 CRP 水平如何,aPTT 和抗-Xa 值均相似。标本中 CRP 升高伴随着纤维蛋白原和 FVIII 活性的增加。额外的体外实验证实,同时加入 CRP 可减轻肝素化标本中 CRP 引起的 aPTT 延长。

结论

由于同时存在 FVIII 增加,儿科 ECMO 样本中未观察到 CRP 诱导的 aPTT 延长。CRP 和 FVIII 在血浆中的变化不一致可能导致儿科人群肝素治疗期间观察到的 aPTT/抗-Xa 差异。抗-Xa 检测更适合儿科 ECMO 环境中的肝素监测。

相似文献

1
C-reactive protein-induced activated partial thromboplastin time prolongation in heparinized samples is attenuated by elevated factor VIII.C 反应蛋白诱导的肝素化样本活化部分凝血活酶时间延长可被升高的因子 VIII 减弱。
Int J Lab Hematol. 2021 Feb;43(1):139-142. doi: 10.1111/ijlh.13314. Epub 2020 Aug 19.
2
Pseudo Heparin Resistance After Pulmonary Endarterectomy: Role of Thrombus Production of Factor VIII.肺血管成形术后假性肝素抵抗:VIII 因子血栓生成的作用。
Semin Thorac Cardiovasc Surg. 2022 Spring;34(1):315-323. doi: 10.1053/j.semtcvs.2021.03.042. Epub 2021 May 10.
3
The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.游离血红蛋白和胆红素对通过活化部分凝血活酶时间和抗Xa测定法进行肝素监测的影响。
Arch Pathol Lab Med. 2014 Nov;138(11):1503-6. doi: 10.5858/arpa.2013-0572-OA.
4
Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation.小儿体外膜肺氧合期间的抗凝监测。
ASAIO J. 2013 Jan-Feb;59(1):63-8. doi: 10.1097/MAT.0b013e318279854a.
5
Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO.重症新型冠状病毒肺炎患者普通肝素的监测:对接受连续性肾脏替代治疗和体外膜肺氧合治疗患者的观察性研究
TH Open. 2020 Nov 19;4(4):e365-e375. doi: 10.1055/s-0040-1719083. eCollection 2020 Oct.
6
Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation Complications.抗因子 Xa、活化部分凝血活酶时间与肝素剂量的相关性及其与儿科体外膜肺氧合并发症的关系。
ASAIO J. 2020 Mar;66(3):307-313. doi: 10.1097/MAT.0000000000000986.
7
Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin.在治疗剂量肝素作用下,凝血因子VIII水平对活化部分凝血活酶时间(APTT)及抗Xa活性的影响。
Int J Hematol. 2015 Feb;101(2):119-25. doi: 10.1007/s12185-014-1702-z. Epub 2014 Nov 23.
8
Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.抗Xa因子水平与活化部分凝血活酶时间用于监测普通肝素:一项初步研究。
J Clin Pharm Ther. 2016 Oct;41(5):499-502. doi: 10.1111/jcpt.12415. Epub 2016 Jul 6.
9
Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation.抗因子 Xa 与 aPTT 在体外膜肺氧合中监测肝素的比较。
Am J Health Syst Pharm. 2023 May 24;80(Suppl 2):S77-S83. doi: 10.1093/ajhp/zxac351.
10
Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial.接受体外膜肺氧合治疗的成人患者中抗Xa因子与活化部分凝血活酶时间的一致性及预后:体外膜肺氧合治疗危重症患者低剂量肝素随机试验的二次分析
Crit Care Explor. 2023 Nov 8;5(11):e0999. doi: 10.1097/CCE.0000000000000999. eCollection 2023 Nov.

引用本文的文献

1
Pitfalls in Argatroban Monitoring: Heparin Interference With Dilute Thrombin Time Assays.阿加曲班监测中的陷阱:肝素对稀释凝血酶时间测定的干扰。
Int J Lab Hematol. 2025 Oct;47(5):989-991. doi: 10.1111/ijlh.14505. Epub 2025 May 26.
2
Efficient and scalable construction of clinical variable networks for complex diseases with RAMEN.利用RAMEN高效且可扩展地构建复杂疾病的临床变量网络
Cell Rep Methods. 2025 Apr 21;5(4):101022. doi: 10.1016/j.crmeth.2025.101022. Epub 2025 Apr 10.
3
C-reactive protein expression in acute ischemic stroke blood clots: Implications for etiology.
急性缺血性中风血凝块中的C反应蛋白表达:对病因学的影响。
Eur Stroke J. 2025 Feb 5:23969873251315636. doi: 10.1177/23969873251315636.
4
Is it time to switch to bivalirudin for ECMO anticoagulation?是时候改用比伐卢定进行体外膜肺氧合(ECMO)抗凝了吗?
Front Med (Lausanne). 2023 Aug 21;10:1237601. doi: 10.3389/fmed.2023.1237601. eCollection 2023.
5
Novel Coagulation Test Detects Anticoagulation Resistance and Is Associated With Thrombotic Events in Pediatric Patients Requiring Extracorporeal Membrane Oxygenation.新型凝血试验可检测抗凝抵抗,并与需要体外膜肺氧合的儿科患者的血栓形成事件相关。
Crit Care Explor. 2022 Oct 25;4(10):e0776. doi: 10.1097/CCE.0000000000000776. eCollection 2022 Oct.
6
Heparin - Messias or Verschlimmbesserung?肝素——救星还是越帮越忙?
J Thromb Haemost. 2021 Oct;19(10):2373-2382. doi: 10.1111/jth.15464. Epub 2021 Jul 29.
7
Updates in Anticoagulation Therapy Monitoring.抗凝治疗监测的进展
Biomedicines. 2021 Mar 6;9(3):262. doi: 10.3390/biomedicines9030262.